Media coverage about Corium International (NASDAQ:CORI) has trended somewhat positive on Monday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Corium International earned a news impact score of 0.21 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.7202379442787 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Corium International (NASDAQ CORI) traded up $0.13 during trading hours on Monday, hitting $10.25. The stock had a trading volume of 46,800 shares, compared to its average volume of 178,829. Corium International has a 12 month low of $2.67 and a 12 month high of $11.37. The company has a debt-to-equity ratio of 1.89, a current ratio of 7.04 and a quick ratio of 6.80.
A number of analysts recently issued reports on the company. Jefferies Group LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Corium International in a research report on Wednesday, July 19th. BidaskClub downgraded Corium International from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. ValuEngine downgraded Corium International from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th. Zacks Investment Research downgraded Corium International from a “buy” rating to a “sell” rating in a research report on Tuesday, October 10th. Finally, Needham & Company LLC reissued a “buy” rating and set a $13.00 price target on shares of Corium International in a research report on Sunday, September 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $13.00.
TRADEMARK VIOLATION NOTICE: This article was first published by Markets Daily and is owned by of Markets Daily. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.themarketsdaily.com/2017/11/13/corium-international-cori-receives-media-sentiment-score-of-0-21.html.
In related news, CAO Timothy D. Sweemer sold 12,012 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $7.62, for a total value of $91,531.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Parminder Singh sold 30,415 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $7.59, for a total value of $230,849.85. Following the completion of the sale, the insider now owns 30,762 shares of the company’s stock, valued at $233,483.58. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 458,015 shares of company stock valued at $4,745,798. Corporate insiders own 45.70% of the company’s stock.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.